ArticleDrug testing and analysis2026
Urinary and Plasma Profiles of Betamethasone and Triamcinolone Acetonide Following Intra-Articular and Related Administrations.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Since 2022, intra-articular (IA) and periarticular (PA) administrations of glucocorticoids (GC) have been prohibited in sports during competitions. The aim of this study was to evaluate plasma and urinary concentrations of betamethasone (BET) and triamcinolone acetonide (TA) following IA and PA administrations, in order to verify the suitability of the minimum reporting levels (MRL) and washout periods established by WADA and to assess their systemic effects. Urine and plasma samples were collected after IA or PA administration in patients or athletes receiving GC treatment. For BET, 12 participants received IA, and 20 received PA injections; for TA, eight participants received IA, and six received PA administrations. Sample analysis was performed using validated LC-MS/MS methods. The elimination profiles of BET after both IA and PA administrations were comparable, with high concentrations observed during the first postadministration day followed by a progressive decline. Similar plasma concentrations were obtained after both routes, with a similar effect on cortisol levels, indicating a clear systemic effect. For TA, different excretion patterns were observed depending on the administration route. After IA injections, TA displayed a profile similar to that of BET. In contrast, following PA administration, TA concentrations in urine and plasma were lower and remained relatively constant over several days. The degree and duration of cortisol suppression after PA administration varied among participants, with some showing a short effect. The results obtained support the MRL for IA and PA administrations defined by WADA. However, the washout period for BET is recommended to be increased to 5 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.